Metallopeptidase Inhibitors for Kidney Protection, Inflammation, and Oncology Research.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for DPEP1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | DPEP1 ECD-Fc / Mutant Protein High purity (>95%), Zinc-binding site preserved, Endotoxin <1EU/ug. Sequence Verified. |
View DPEP1 Products |
| Gene Delivery | DPEP1 ORF Lentivirus Full-length ORF with GPI-anchor signal for brush border membrane localization; suitable for stable cell lines. |
View DPEP1 Products |
| Detection Ab / Benchmark Ab | Anti-DPEP1 Antibody (Recombinant Biosimilar Control) For Western/IHC validation and binding assays. |
View DPEP1 Products |
| Validator | DPEP1 siRNA Set (3 unique clones) For knockdown verification and off-target specificity controls. |
View DPEP1 Products |
| Isoform Control | DPEP2 Protein Counter-screening for metallopeptidase selectivity (DPEP family). |
View DPEP2 Products |
| Pathway Partner | GGT1 Protein Gamma-glutamyl transferase for glutathione metabolism pathway studies. |
View GGT1 Products |
| Related Target A | CEACAM5 Synergistic target often co-expressed in colorectal cancer; for combinatorial ADC/bispecific strategies. |
View CEACAM5 Products |
| Related Target B | TROP2 Broad pan-tumor epithelial marker for combinatorial ADC strategies. |
View TROP2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Zinc-dependent catalytic activity requires correct metal coordination | HEK293 Expressed (Native Glycosylation), Metal-ion coordinated, Theoretical MW verified by mass spec |
| Cross-species PK/PD / tox evaluation (Human/Mouse/Rat/Cyno) | Human, Mouse, Rat, and Cyno ortholog proteins available with >95% purity, Sequence Verified |
| Metallopeptidase family selectivity (vs DPEP2/DPEP3/MMPs) | Homolog panel proteins strictly verified by mass spec for selectivity profiling; DPEP2/DPEP3 cross-reactivity controls included |
| False Positives in inhibition assays | Validated siRNA included for target-specificity confirmation |
| Membrane localization for transport/uptake studies | Lentivirus with GPI-anchor signal for polarized epithelial cell lines (MDCK, HK-2) |
| Lack of positive/negative controls | Clinical Benchmark Antibodies (Biosimilars) included as assay controls |
Live DPEP1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for DPEP1 therapeutics is intensifying along two major axes: kidney protection and oncology/inflammation. On the renal front, traditional antibiotic adjuvants (e.g., cilastatin analogs) are evolving into next-generation nephroprotective agents for acute kidney injury (AKI) and drug-induced nephrotoxicity. DPEP1's role in glutathione metabolism and oxidative stress is driving development of small molecule inhibitors targeting AKI and fibrotic kidney disease. Simultaneously, DPEP1's overexpression in colorectal, pancreatic, and lung adenocarcinomas positions it as a prime tumor-associated antigen for antibody-drug conjugates (ADCs), radiopharmaceuticals, and CAR-T therapies. The peptide inhibitor LSALT (Arch Biopartners) is advancing in clinical trials for AKI and inflammation by blocking DPEP1-mediated leukocyte recruitment. As first-generation therapies enter the clinic, future R&D is expected to focus on highly internalized ADC constructs, dual-targeting bispecifics, and kidney-specific prodrug strategies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Generic Cilastatin Analogs, Novel Zinc-Binders | Drug-Induced Nephrotoxicity, AKI | Enzymatic Inhibition Assay (Need high-purity zinc-coordinated enzyme) |
| Peptide Inhibitors | Arch Biopartners (LSALT) | Acute Kidney Injury, Inflammation | Enzymatic Assay Controls (Need High-Purity ECD) |
| ADC / Radioligand | Preclinical Biotech | Colorectal Cancer, Pancreatic Cancer | Internalization Assay (Need HEK293 Expressed ECD-Fc) |
| CAR-T / Bispecifics | Academic / Early Biotech | Solid Tumors | Binding Specificity (Need Homolog Negative Controls) |
| Targeted Protein Degradation | Emerging Academic Programs | Fibrotic Kidney Disease | Cell Line Construction (Need Lentivirus for stable DPEP1-KO rescue) |
| Biomarker Development | Diagnostic Companies | Renal Function Monitoring | Specificity Verification (Need DPEP2/3 cross-reactivity panels) |
Strategic Cross-Selling Opportunities
- DPEP2 (View DPEP2 Products): Isoform control for selectivity profiling; highly expressed in lung epithelium, critical for respiratory indication screening.
- GGT1 (View GGT1 Products): Pathway partner in glutathione metabolism; co-regulated with DPEP1 in AKI and fibrosis studies.
- CEACAM5 (View CEACAM5 Products): Co-expressed in colorectal cancer; synergistic target for dual-ADC/bispecific strategies.
- TROP2 (View TROP2 Products): Broad epithelial marker for pan-tumor combination therapy screening.
Recommended Assay Development Workflow
- Biochemical Screening: DPEP1 ECD-Fc inhibition assay (substrate: Glycyl-L-leucine or fluorogenic probe); include zinc concentration gradient (0.1-10 µM) to exclude metal chelation artifacts.
- Selectivity Panel: Counter-screen against DPEP2, DPEP3, DPP4, MMP-2/9 using validated homolog proteins.
- Cellular Functional Validation: Lentivirus-based overexpression cell lines (MDCK/HK-2) for drug uptake protection and GSH/GSSG ratio measurements.